Chemotherapy benefit for ‘ER-positive’ breast cancer and contamination of Nonluminal subtypes—waiting for TAILORx and RxPONDER

le Sun, Z., Prat, A., Cheang, M.C.U., Gelber, R.D., Perou, C.M.
Foilsithe in Ann Oncol (2015)

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen

le Prat, A., Parker, J. S., Fan, C., Cheang, M. C. U., Miller, L. D., Bergh, J., Chia, S. K. L., Bernard, P. S., Nielsen, T. O., Ellis, M. J., Carey, L. A., Perou, C. M.
Foilsithe 2012

Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial

le Sipos, O., Tovey, H., Quist, J., Haider, S., Nowinski, S., Gazinska, P., Kernaghan, S., Toms, C., Maguire, S., Orr, N., Linn, S.C., Owen, J., Gillett, C., Pinder, S.E., Bliss, J.M., Tutt, A., Cheang, M.C.U., Grigoriadis, A.
Foilsithe in Ann Oncol (2021)

Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES

le Cheang, M. C. U., Bliss, J. M., Viale, G., Speirs, V., Palmieri, C., Shaaban, A., Lønning, P. E., Morden, J., Porta, N., Jassem, J., van De Velde, C. J., Rasmussen, B. B., Verhoeven, D., Bartlett, J. M. S., Coombes, R. C.
Foilsithe in Breast Cancer Res Treat (2017)

Predicting response and survival in chemotherapy-treated triple-negative breast cancer

le Prat, A, Lluch, A, Albanell, J, Barry, W T, Fan, C, Chacón, J I, Parker, J S, Calvo, L, Plazaola, A, Arcusa, A, Seguí-Palmer, M A, Burgues, O, Ribelles, N, Rodriguez-Lescure, A, Guerrero, A, Ruiz-Borrego, M, Munarriz, B, López, J A, Adamo, B, Cheang, M C U, Li, Y, Hu, Z, Gulley, M L, Vidal, M J, Pitcher, B N, Liu, M C, Citron, M L, Ellis, M J, Mardis, E, Vickery, T, Hudis, C A, Winer, E P, Carey, L A, Caballero, R, Carrasco, E, Martín, M, Perou, C M, Alba, E
Foilsithe 2014